Glecaprevir + Pibrentasvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Glecaprevir- 100 mg + Pibrentasvir - 40 mg
Reference Brands: Mavyret (US); Maviret (EU)
Category: Anti Viral
Mavyret/Maviret is a once-daily 3-tablet regimen combining Glecaprevir and Pibrentasvir for pan-genotypic HCV treatment. It offers short 8-week therapy, high cure rates, and is safe for patients with kidney or liver issues.
Product Description:
Mavyret (US) / Maviret (EU) is a fixed-dose combination of Glecaprevir 100 mg and Pibrentasvir 40 mg per tablet, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across genotypes 1–6. This pan-genotypic regimen is taken as three tablets once daily with food. It offers one of the shortest HCV treatments—just 8 weeks for most patients. Mavyret is highly effective (SVR >95%) and suitable for use in patients with renal impairment and compensated cirrhosis. Its ribavirin-free formulation improves tolerability, making it a convenient, high-efficacy option for diverse patient populations.
Glecaprevir + Pibrentasvir — third party manufacturing & bulk supply
Glecaprevir + Pibrentasvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Glecaprevir + Pibrentasvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Glecaprevir + Pibrentasvir →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Glecaprevir and Pibrentasvir are used together for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1–6). This combination is highly effective and is used in both treatment-naïve and treatment-experienced patients, with or without cirrhosis.
This fixed-dose combination contains glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor. Together, they block viral replication at two different stages of the HCV life cycle, leading to sustained virologic response.
The globally recognized trade name for this combination is Mavyret (also known as Maviret in some regions).
Mavyret/Maviret is manufactured by AbbVie.
The generic name of the product is glecaprevir and pibrentasvir.
The common brand name is Mavyret (or Maviret depending on the market).
Glecaprevir + Pibrentasvir (Mavyret/Maviret) is manufactured by AbbVie in its approved global pharmaceutical production facilities located in the United States and Europe. Generic versions, where permitted, are produced by licensed manufacturers in select countries.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
